What the FDA labels say about taking them together
Methylene blue and trazodone
Trazodone's FDA label of January 22, 2026 names methylene blue in its contraindications section; methylene blue's label does not name trazodone itself but warns about its class (serotonin reuptake inhibitors). The trazodone label: “The concomitant use of MAOIs and serotonergic drugs including RALDESY increases the risk of serotonin syndrome.”
Check it at the source: the methylene blue FDA label on DailyMed (effective May 28, 2025, American Regent, Inc.); the trazodone FDA label on DailyMed (effective January 22, 2026, Zydus Pharmaceuticals USA Inc.).
What does the methylene blue label say about trazodone?
Methylene blue's label does not name trazodone itself; it warns about its class (serotonin reuptake inhibitors):
Methylene blue label, drug interactionsAvoid concomitant use of PROVAYBLUE with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome.
Methylene blue label, boxed warningAvoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )].
Source: FDA drug label (PROVAYBLUE), NDA204630 (Provepharm Sas), as published by American Regent, Inc., effective May 28, 2025 (SPL set 4f6848e5-35ed-4046-b13c-3032b5ba3232), via openFDA; the full label on DailyMed
What does the trazodone label say about methylene blue?
Trazodone label, contraindicationsTrazodone hydrochloride tablets are contraindicated in: Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )].
Trazodone label, drug interactionsIntervention; Trazodone is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4), Dosage and Administration (2.3, 2.4), and Warnings and Precautions (5.2)].
Trazodone label, warnings and precautionsIf it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking trazodone, discontinue trazodone before initiating treatment with the MAOI [see Contraindications ( 4 ), Drug Interactions ( 7.1 )].
Raldesy Tm label (Validus Pharmaceuticals LLC, September 1, 2026), drug interactionsMonoamine Oxidase Inhibitors (MAOIs) Clinical Impact: The concomitant use of MAOIs and serotonergic drugs including RALDESY increases the risk of serotonin syndrome. Intervention: RALDESY is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see, Dosage and Administration (,, and ].
Source: FDA drug label (Raldesy Tm, NDA218637), Validus Pharmaceuticals LLC, effective September 1, 2026 (SPL set 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9), via openFDA
Source: FDA drug label (Trazodone Hydrochloride), Zydus Pharmaceuticals USA Inc., effective January 22, 2026 (SPL set 704aebf9-2fff-4ef3-8323-9ff0d7f0ffd9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methylene blue | Trazodone | |
|---|---|---|
| Labeled for | n/a | Depression |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.0307 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once